Skip to main content
    Woman in midlife talking with her care team
    Last updated

    GLP-1 medications for weight management in perimenopause and menopause

    Clinically reviewed by Eva Luo, MD, MBA, FACOG, Head of Women’s Health at Pomelo

    Weight changes during perimenopause and menopause can feel frustrating, and more people are asking whether a GLP-1 medication such as Wegovy or Zepbound could help. These medications can be effective, but they aren’t right for everyone. They don’t treat menopause symptoms (e.g., hot flashes, mood changes, sleep challenges) directly, but weight loss has been linked with improvement in hot flashes and sleep. This guide explains how weight and body composition change during perimenopause and menopause, who may be a candidate for a GLP-1, what the medications cost, the risks and side effects, and what to ask before you start.

    Why weight and body shape change during perimenopause and menopause

    Much of the change comes from the amount of fat versus muscle your body has, not just the number on the scale.

    The Study of Women’s Health Across the Nation (SWAN), a long-running US study that followed about 1,200 women with body scans through the menopause transition, found that scale weight rose gradually over time without a sudden jump at menopause. Underneath, though, the rate of fat gain roughly doubled starting about two years before the final menstrual period, and lean mass began to decline. Those shifts leveled off about two years after the final period.

    Researchers think falling estrogen plays a role, since estrogen influences where the body stores fat and how it handles insulin, though the mechanisms are still being studied. Poor sleep, mood changes, and less physical activity can add to it. This is about more than just willpower, and it also doesn’t mean medication is the only answer. Strength training, eating enough protein, and getting adequate sleep are the foundation, with medication as one option for people who qualify.

    What GLP-1 medications are

    GLP-1 medications mimic gut hormones that help regulate appetite and blood sugar. They make your stomach empty more slowly, which helps you feel full sooner and longer. Two brand-name options widely prescribed for weight management include:

    • Wegovy (semaglutide) comes as a weekly injection or a daily pill. It is also approved to lower the risk of heart attack, stroke, and cardiovascular death in adults with known heart disease and either obesity or overweight.
    • Zepbound (tirzepatide) is a weekly injection that acts on two gut hormone pathways. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

    Both are meant to be used with a reduced-calorie diet and more physical activity, and both require a prescription.

    Who may be a candidate

    A clinician decides this after reviewing your history. In general:

    • Adults with a body mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, may qualify.
    • A GLP-1 is generally not appropriate if you or a family member has had medullary thyroid carcinoma or MEN 2, if you’ve had a serious allergic reaction to the medication, or if you are pregnant or trying to become pregnant.
    • It is not recommended for people with severe gastroparesis, and a history of pancreatitis, gallbladder disease, kidney problems, or diabetic eye disease calls for extra caution.

    BMI is an imperfect measure, particularly during perimenopause and menopause, when body composition shifts. A good clinician looks at your overall health, not a single number.

    What results to expect

    Results vary widely from person to person. They depend on the medication, the dose you can tolerate, how long you take it, and changes to your diet and activity levels. Weight loss in clinical trials is an average across many people, and individual results differ. Your clinician can walk you through what to realistically expect for the specific medication and dose.

    Risks and side effects

    Common side effects are mostly digestive and often ease over time:

    • Common: nausea, vomiting, diarrhea, constipation, and stomach pain, most often when starting or increasing a dose. In trials these were mostly mild to moderate.
    • Less common but serious: pancreatitis, gallbladder problems, dehydration that can lead to kidney injury, and severe allergic reactions. Call your care team immediately for severe or persistent stomach pain, vomiting so much you can’t keep fluids down, or swelling of the face or throat.
    • Thyroid warning: the labels carry a boxed warning because these medications caused thyroid tumors in rodents. It isn’t known whether they do in humans, which is why they’re not used in people with certain personal or family histories.
    • Low blood sugar: this is more likely if you also take insulin or a sulfonylurea, so those doses may need adjusting.
    • Muscle loss: weight loss from any method can include lean mass, not just fat. Because lean mass already tends to decline in the menopause transition, protein intake and strength training matter.
    • Surgery and anesthesia: these medications slow stomach emptying, so tell your surgical team you take one before any procedure.

    Contraception and pregnancy deserve their own mention.

    If you’re still having periods, you can still get pregnant, even in perimenopause. Research on GLP-1s in pregnancy is still evolving, and their safety hasn’t been well established, including the risk of birth defects or other problems such as preterm birth. Because of these unknowns, GLP-1s are not recommended during pregnancy.

    GLP-1s also slow how quickly the stomach empties, which can change how well oral medications are absorbed. That may include oral birth control and oral hormone therapy for perimenopause and menopause symptoms, which may work less well for a period of time after you start a GLP-1 or increase your dose. For oral contraceptives, Zepbound’s labeling advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. Ask your clinician what applies to your medication.

    What happens if you stop

    Weight regain after stopping is common. In one trial of tirzepatide, people who lost weight over 36 weeks and then switched to placebo regained a meaningful amount of the weight they had lost, and some improvements in blood pressure, cholesterol, and blood sugar reversed along with it. People who continued treatment were more likely to keep the weight off.

    This doesn’t mean everyone has to stay on a GLP-1 forever. It means the plan for stopping, adjusting the dose, or maintaining weight should be discussed before you start, not after.

    How GLP-1s fit with hormone therapy and other menopause care

    GLP-1s and hormone therapy do different jobs. Hormone therapy treats symptoms such as hot flashes, night sweats, and vaginal dryness, and it isn’t a weight-loss treatment. A GLP-1 supports weight management and doesn’t treat those symptoms directly. Some people use both when each is appropriate for them.

    Because GLP-1s slow stomach emptying, they can change how some oral medications are absorbed. Tell your clinician about everything you take, including oral hormone therapy and birth control. Sleep, stress, nutrition, and mental health also shape how you feel and how your weight changes, so care that looks at the whole picture tends to work better than a prescription alone.

    What GLP-1 medications cost

    Cost has two parts: the visit and the medication. Both vary.

    • Visits: GLP-1 care typically includes an initial visit and ongoing follow-up visits. Most Pomelo patients pay $25 or less per visit with in-network insurance. Without insurance, as of November 2026, cash-pay care is $49 for the first month of membership and then $125 a month, or you can pay per visit starting at $195. Prices are subject to change, and medication is billed separately.
    • Wegovy (manufacturer cash price through NovoCare): the daily pill is $149 a month at the 1.5 mg starting dose, $199 at 4 mg, and $299 at the 9 mg and 25 mg doses. The weekly injection is $349 a month, with a temporary introductory price for new patients on the lowest doses through December 31, 2026.
    • Zepbound (manufacturer cash price through LillyDirect): $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg and above when each refill is made within 45 days. Late refills at higher doses cost more, and needles and syringes are sold separately.
    • With insurance: if your plan covers the medication, manufacturer savings offers can bring a commercially insured patient’s cost down to as little as $25 a month, within program limits. Coverage for weight-loss medication varies widely, and government insurance plans are usually excluded from these offers.

    Prices listed above are current as of November 2026. Prices are set by the manufacturers and change often. Check the manufacturer’s site for today’s price before you decide.

    Questions to ask before you start a GLP-1

    • Is a GLP-1 appropriate for my health history, and why this medication?
    • Should I take a pill or an injection, and what are the trade-offs?
    • What will I pay for visits and for each dose, with and without insurance?
    • How will we protect my muscle mass, and who can help me with nutrition?
    • Which side effects should I call my provider about right away?
    • What’s the plan if I want to stop, change doses, or become pregnant?
    • Do you or your company earn more if I take a prescription? Is the medication FDA-approved or compounded?

    Your Pomelo clinician can answer your questions and discuss whether GLP-1s are right for you. Book a visit today.

    Red flags to watch for in GLP-1 programs

    • No individual medical evaluation, or a prescription that seems guaranteed before you’ve been assessed
    • Compounded or “custom” semaglutide or tirzepatide marketed as the same as Wegovy or Zepbound. Compounded versions are not FDA-approved
    • Pressure to buy multi-month bundles, supplements, or add-ons
    • No clear plan for follow-up, side effects, dose changes, or stopping
    • Prices or insurance claims that are hard to verify or don’t mention that costs rise with dose
    • Promises of specific weight loss or a “quick fix”

    How Pomelo approaches GLP-1 care

    Pomelo offers virtual perimenopause and menopause care with menopause-specialist medical doctors and nurse practitioners, registered dietitians, and therapists working together. Your clinician reviews your history and decides whether a GLP-1 is appropriate. Pomelo prescribes only when it’s clinically appropriate after an individual evaluation, and if it isn’t, your team builds a different plan with you. Your dietitian can help you build a protein-forward eating plan to protect muscle, and your therapist can support you with “food noise” and the stress that often comes with weight and hormone changes. Dietitian and therapist visits are strongly recommended for GLP-1 patients.

    Pomelo prescribes FDA-approved medication only and does not prescribe compounded versions. Prescriptions go to the manufacturer’s pharmacy (LillyDirect or NovoCare) or your local pharmacy. Pomelo doesn’t sell medications and doesn’t make more money based on what is prescribed.

    Pomelo accepts select insurance plans in California, Colorado, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, and Virginia. Most patients pay $25 or less for visits with in-network insurance, and Pomelo verifies your coverage before care begins. Coverage for the medication itself is set by your plan and is separate from visit coverage. Coverage changes as we add plans and states, so check our current coverage before you sign up.

    GLP-1 medications are available by prescription only and are not right for everyone. Care models differ, and the right fit depends on your health, goals, and budget. Use the questions above to compare any provider, including us. Wegovy is a registered trademark of Novo Nordisk. Zepbound and LillyDirect are registered trademarks of Eli Lilly and Company. Pomelo is not affiliated with either company.

    Not sure if a GLP-1 is right for you? Book a visit to talk it through with a menopause specialist, or check your insurance coverage.

    Frequently asked questions

    Will I get a GLP-1 prescription?

    Not automatically. A clinician reviews your health history, goals, and any health conditions or medications that affect safety before deciding. If a GLP-1 isn’t right for you, your care team can help you build a different plan.

    Do GLP-1s treat hot flashes or other menopause symptoms?

    Not directly. GLP-1s are approved for weight management, not for menopause symptoms, and haven’t been shown to treat them directly. Some research links weight loss with fewer hot flashes. Hot flashes, night sweats, and sleep problems have their own treatments, including hormone therapy and non-hormonal options.

    Can I take a GLP-1 and hormone therapy together?

    Many people can, when each is appropriate for them. Because GLP-1s slow stomach emptying and can affect how oral medications are absorbed, your clinician needs a complete list of everything you take.

    Do GLP-1s cause muscle loss?

    Weight loss from any method can include some lean mass. Because lean mass already tends to decline during the menopause transition, it’s important to prioritize eating enough protein and strength training. Ask your care team how they’ll monitor this.

    Can I use a GLP-1 if I could still get pregnant?

    These medications are not recommended for use during pregnancy, and some may reduce the effectiveness of oral birth control. Talk with your clinician about contraception before you start, and let them know if you’re trying to conceive.

    Are compounded GLP-1s the same as Wegovy or Zepbound?

    No. Compounded versions are made by pharmacies and are not FDA-approved, so they haven’t been reviewed for safety, effectiveness, or quality the way Wegovy and Zepbound have. Ask any provider whether the medication they prescribe is FDA-approved.

    Does insurance cover GLP-1 medication?

    It depends on your plan. Many plans cover visits but not weight-loss medication, and some require prior authorization. Manufacturer savings offers generally require commercial insurance, and manufacturer cash prices are an option if your plan doesn’t cover the medication.

    How long will I need to take a GLP-1?

    It varies. Many people regain weight after stopping, so clinicians often treat weight management as long-term care. Your plan for continuing, adjusting, or stopping should be part of your first conversation.

    What happens if I want to stop?

    Talk with your care team first. They can help you decide when and how to stop or lower your dose, and how to protect your progress with nutrition and strength training.

    Sources:

    1. Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight, 2019.
    2. U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information.
    3. Novo Nordisk. Wegovy (semaglutide) cost, coverage, and savings. NovoCare.
    4. Eli Lilly and Company. Zepbound self-pay pricing and program terms. LillyDirect.
    5. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024;331(1):38–48.
    6. Horn DB, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Internal Medicine, 2026.
    7. Marlatt KL, et al. Body composition and cardiometabolic health across the menopause transition. Obesity (Silver Spring), 2022;30(1):14–27.
    8. Huang AJ, et al. An intensive behavioral weight loss intervention and hot flushes in women. Archives of Internal Medicine, 2010;170(13):1161–1167.
    9. The Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 2023;30(6):573–590.
    10. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine, 2024;391(13):1193–1205.